First Clinical Trial of New Targeted Molecular Therapy in U.S. Takes Aim at Incurable Prostate Cancer
NewYork-Presbyterian and Weill Cornell Medicine clinicians in progress on Phase 1 clinical trial of PSMA-Targeted Therapeutic Agent for the Treatment for Metastatic Prostate Cancer
NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the U.S. that uses a small molecule, 177Lu-PSMA-617, to treat men with progressive prostate cancer that has spread beyond the prostate, or is metastatic, and is no longer responding to hormonal therapy.
Dr. Bander completed fellowship training in clinical urological oncology under Dr. Willet F. Whitmore, Jr., and an NIH Immunology Training Fellowship in the laboratory of Dr. Lloyd Old, both at Memorial Sloan-Kettering Cancer Center. After coming to NYPH-Weill Cornell, he focused on clinical urological oncology and the development of monoclonal antibodies for targeted cancer therapy. He has directed both a laboratory and translational clinical research program.